Buscar
Aligos Therapeutics Inc
ALGSAñadir a la lista de seguimiento
5.450USD
-0.320-5.55%
Cierre 07/01, 16:00（ET）Cotizaciones retrasadas 15 min
33.73MCap. mercado
PérdidaP/E TTM
Más Datos de Aligos Therapeutics Inc Compañía
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Información de Aligos Therapeutics Inc
Símbolo de cotizaciónALGS
Nombre de la empresaAligos Therapeutics Inc
Fecha de salida a bolsaOct 16, 2020
Director ejecutivoBlatt (Lawrence M)
Número de empleados70
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 16
DirecciónOne Corporate Dr., 2Nd Floor
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono18004666059
Sitio Webhttps://www.aligos.com/
Símbolo de cotizaciónALGS
Fecha de salida a bolsaOct 16, 2020
Director ejecutivoBlatt (Lawrence M)
Ejecutivos de Aligos Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
88.42K
--
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
35.11K
+55.11%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
5.22K
+30.85%
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Ms. Carole L. Nuechterlein, J.D.
Ms. Carole L. Nuechterlein, J.D.
Independent Director
Independent Director
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Mr. Jordyn Tarazi
Mr. Jordyn Tarazi
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Dr. Heather Preston, M.D.
Dr. Heather Preston, M.D.
Independent Director
Independent Director
--
--
Ms. Margarita Chavez, J.D.
Ms. Margarita Chavez, J.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
88.42K
--
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
35.11K
+55.11%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
5.22K
+30.85%
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Ms. Carole L. Nuechterlein, J.D.
Ms. Carole L. Nuechterlein, J.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Aligos Therapeutics Inc?
Los cinco principales accionistas de Aligos Therapeutics Inc son: Dr. Lawrence M. Blatt, Ph.D.
¿Cuántas instituciones poseen acciones de Aligos Therapeutics Inc (ALGS)?
A fecha de 2026Q1, 108 instituciones poseen acciones de Aligos Therapeutics Inc, con un valor de mercado combinado de aproximadamente 2.82M, lo que representa el 52.29% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1521590.00.